What is the current status of ovarian suppression/ablation in women with premenopausal early-stage breast cancer?
Authors:
- Michaela J. HigginsMHMichaela J. Higgins
- Nancy E. DavidsonNDNancy E. Davidson
- 1 March 2009
- journal article
- research article
- Published by Springer Nature in Current Breast Cancer Reports
- Vol. 1 (1) , 42-47
Abstract
No abstract availableKeywords
This publication has 31 references indexed in Scilit:
- Estrogen suppression in premenopausal women following 8 weeks of treatment with exemestane and triptorelin versus triptorelin aloneBreast Cancer Research and Treatment, 2008
- Is chemotherapy necessary for premenopausal women with lower-risk node-positive, endocrine responsive breast cancer? 10-year update of International Breast Cancer Study Group Trial 11-93Breast Cancer Research and Treatment, 2008
- Effect of Systemic Adjuvant Treatment on Risk for Contralateral Breast Cancer in the Women's Environment, Cancer and Radiation Epidemiology StudyJNCI: Journal of the National Cancer Institute, 2008
- Ovarian protection with goserelin during adjuvant chemotherapy for pre-menopausal women with early breast cancer (EBC)Breast Cancer Research and Treatment, 2007
- Ovarian Ablation or Suppression in Premenopausal Early Breast Cancer: Results From the International Adjuvant Breast Cancer Ovarian Ablation or Suppression Randomized TrialJNCI: Journal of the National Cancer Institute, 2007
- Zoledronic Acid Prevents Cancer Treatment–Induced Bone Loss in Premenopausal Women Receiving Adjuvant Endocrine Therapy for Hormone-Responsive Breast Cancer: A Report From the Austrian Breast and Colorectal Cancer Study GroupJournal of Clinical Oncology, 2007
- Similar Efficacy for Ovarian Ablation Compared With Cyclophosphamide, Methotrexate, and Fluorouracil: From a Randomized Comparison of Premenopausal Patients With Node-Positive, Hormone Receptor–Positive Breast CancerJournal of Clinical Oncology, 2006
- Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trialsThe Lancet, 2005
- Effects of Adjuvant Tamoxifen and of Cytotoxic Therapy on Mortality in Early Breast CancerNew England Journal of Medicine, 1988
- ON THE TREATMENT OF INOPERABLE CASES OF CARCINOMA OF THE MAMMA: SUGGESTIONS FOR A NEW METHOD OF TREATMENT, WITH ILLUSTRATIVE CASES.1The Lancet, 1896